Nitai Riegler, MD
Internal Medicine · Milford, CTNPI 1225124514
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 470 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,319 and has fallen 83.9% since, to $374 in 2025. Among internal medicine clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 470 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Arbor Pharmaceuticals, Inc.$842
- Johnson & Johnson$663
- Merck$652
- Boehringer Ingelheim$566
- plus $2K from 19 others
What the payments were for
- Food & beverage$8,205100%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 87 | $1,656 |
| GSK | 73 | $1,388 |
| Arbor Pharmaceuticals, Inc. | 68 | $842 |
| Johnson & Johnson | 40 | $663 |
| Merck | 52 | $652 |
| Boehringer Ingelheim | 27 | $566 |
| Lilly USA, LLC | 14 | $508 |
| Novo Nordisk | 30 | $457 |
| Amarin Pharma, Inc. | 13 | $310 |
| AbbVie(2 entities) | 15 | $203 |
| Pfizer | 14 | $202 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Verona Pharma, Inc. | 1 | $113 |
| Amgen | 5 | $81 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $72 |
| Philips North America LLC | 4 | $62 |
| Eisai Inc. | 4 | $57 |
| Electromed, Inc. | 4 | $49 |
| Hikma Pharmaceuticals USA | 3 | $47 |
| Advanced Respiratory, Inc | 3 | $41 |
| Mylan Specialty L.p. | 2 | $40 |
| Eyevance Pharmaceuticals LLC | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Dexcom, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,231 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 99 | $102,817 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $95,337 |
| JardianceEmpagliflozin | 55 | $63,605 |
| RybelsusSemaglutide | 51 | $61,493 |
| FarxigaDapagliflozin Propanediol | 61 | $58,962 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $45,215 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 76 | $38,777 |
| EliquisApixaban | 51 | $37,774 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 20 | $13,815 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $7,531 |
| NamzaricMemantine Hcl/Donepezil Hcl | 11 | $6,391 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,160 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,355 |
| Dexlansoprazole DrDexlansoprazole | 20 | $5,079 |
| VascepaIcosapent Ethyl | 15 | $5,075 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $457 | $164,309150 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,388 | $134,114186 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,656 | $111,709136 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat, Stiolto Respimat | $566 | $88,93598 claims |
| PfizerEliquis | $202 | $37,77451 claims |
| AbbVieNamzaric, Synthroid | $203 | $10,28654 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Milford
- Steven SaundersMilford$49K
- Gary SpectorMilford$32K
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$1.6M
- Arthur DecillisMadison$1M
- Charles MontanoCromwell$970K
- Gary BlickNorwalk$683K
- Scott GottliebStamford$508K
- Jeffrey KatzOxford$361K
- Nicholas DainiakBridgeport$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.